Microsatellite Instability in Inflammatory Bowel Disease-associated Neoplastic Lesions Is Associated with Hypermethylation and Diminished Expression of the DNA Mismatch Repair Gene, hMLH1

A. Steven Fleisher,² Manel Esteller,² Noam Harpaz, Anatoly Leytin, Asma Rashid, Yan Xu, Jing Liang, O. Colin Stine, Jing Yin, Tong-Tong Zou, John M. Abraham, Dehe Kong, Keith T. Wilson, Stephen P. James, James G. Herman, and Stephen J. Meltzer³

Department of Medicine, Gastroenterology Division [A. S. F., Y. X., J. L., J. Y., T.-T. Z., J. M. A., D. K., K. T. W., S. P. J., S. J. M.]; Greenbaum Cancer Center [S. J. M.]; Program in Genetics [A. R., O. C. S.]; Department of Pathology [D. K.]; and Molecular and Cell Biology Graduate Program [J. L., S. J. M.], University of Maryland School of Medicine and Baltimore Veterans Affairs Hospital, Baltimore, Maryland 21210; The Johns Hopkins Oncology Center, Baltimore, Maryland 21231 [M. E., J. G. H.]; and Department of Pathology, Mt. Sinai School of Medicine of New York University, New York, New York 10021 [N. H., A. L.]

ABSTRACT

Twelve to 15% of sporadic colorectal cancers display defective DNA mismatch repair (MMR), manifested as microsatellite instability (MSI). In this group of cancers, promoter hypermethylation of the MMR gene hMLH1 is strongly associated with, and believed to be the cause of, MSI. A subset of colorectal neoplastic lesions arising in inflammatory bowel disease (IBD) is also characterized by MSI. We wished to determine whether MSI was hypermethylation was associated with diminished hMLH1 protein expression and MSI in IBD neoplasms. We studied 148 patients with IBD neoplasms, defined as carcinoma or dysplasia occurring in patients with ulcerative colitis or Crohn’s disease. MSI was evaluated using multiplex fluorescent PCR to amplify loci D2S123, BAT-25, BAT-26, DSS46, and D175259 in all cases. Lesions were characterized as high-frequency MSI (MSI-H) if they manifested instability at two or more loci, low-frequency MSI (MSI-L) if unstable at only one locus, or MS-stable (MSS) if showing no instability at any loci. Methylation-specific PCR was performed to determine the methylation status of the hMLH1 promoter region. hMLH1 protein expression was also evaluated by immunohistochemistry. Thirteen (9%) of 148 neoplasms arising in IBD were MSI-H, comprising 11 carcinomas and 2 dysplastic lesions. Sixteen additional lesions (11%) were MSI-L, comprising 11 carcinomas and 5 dysplastic lesions. The remaining 118 neoplasms (80%) were MSS. Six (46%) of 13 MSI-H, 1 (6%) of 16 MSI-L, and 4 (15%) of 27 MSS lesions showed hMLH1 hypermethylation (P = 0.013). Diminished hMLH1 protein expression in neoplastic cell nuclei relative to surrounding normal cell nuclei was demonstrated immunohistochemically in four of four (100%) hypermethylated lesions tested. In IBD neoplasia, hMLH1 promoter hypomethylation occurs frequently in the setting of MSI, particularly MSI-H. Furthermore, hMLH1 hypermethylation and MSI are strongly associated with diminished hMLH1 protein expression in IBD neoplasms. These findings suggest that hMLH1 hypermethylation causes defective DNA MMR in at least a subset of IBD neoplasms.

INTRODUCTION

CRC is the most dreaded complication of IBD. The development of CRC is the most serious long-term complication faced by patients with longstanding extensive ulcerative colitis and Crohn’s colitis, with an incidence 20-fold higher and an average age of onset 20 years younger than CRC in the general population (1). It is generally accepted that this increased risk does not begin until 8–10 years after the diagnosis of IBD. Therefore, it increases by ~0.5–1.0% per year (2–4). The most significant predictor of the risk of malignancy in IBD is the presence of dysplasia on colonic biopsies. Colonoscopy with biopsies for dysplasia can help stratify patients into risk groups. However, the effectiveness of surveillance programs has been questioned (2). The discovery of new molecular alterations may lead to the development of more accurate screening biomarkers (5).

MSI comprises length mutations in tandem oligonucleotide repeats, which occur in a large subset of human tumors (6–9). This type of mutation is believed to be caused by deficient DNA MMR (10–13). Twelve to 15% of sporadic CRCs display defective DNA MMR, manifested as MSI (14). The underlying cause of MSI in CRC has been the subject of intensive research. Mutations in known MMR genes have been described in kindreds with CRCs meeting the Amsterdam criteria for the diagnosis of hereditary nonpolyposis colon cancer (15). Initially, germ line mutations in the hMSH2 gene were described; subsequently, mutations were also reported in other MMR genes, namely hMLH1, hPMS1, hPMS2, hMSH3 (DUG), and hMSH6 (GTBP) (16–22). However, the majority of sporadic CRCs with MSI do not harbor mutations in known MMR genes (14, 23). In sporadic CRCs, hypermethylation involving the promoter region of the MMR gene hMLH1 is strongly associated with, and widely believed to cause, MSI. Moreover, in MSI-positive sporadic gastric and endometrial tumors, hMLH1 gene promoter hypermethylation is very frequent and is often accompanied by down-regulated or absent hMLH1 gene expression (24–27). This type of epigenetic gene inactivation is not limited to hMLH1. Hypermethylation of normally unmethylated CpG islands in the promoter regions of multiple tumor suppressor genes, including p16, p15, VHL, E-cadherin, GSTP1, and MGMT, suggests an alternative mechanism of gene inactivation (28, 29). A subset of colorectal neoplasms arising in IBD is also characterized by MSI (30, 31). Therefore, we sought to ascertain whether hMLH1 hypermethylation occurred, and whether it was associated with diminished hMLH1 protein expression and MSI, in IBD neoplasms.

MATERIALS AND METHODS

We defined IBD neoplasia as any colorectal dysplasia or carcinoma arising in patients with ulcerative colitis or Crohn’s colitis. One hundred forty-eight samples from patients with IBD neoplasia were analyzed. Samples were obtained consecutively from patients presenting to the Mt. Sinai University Medical Center after informed consent, in compliance with internal institutional board review. Tissues were stored at −180°C until study. DNA was extracted using a previously described technique (32). Parallel morphological sections were used for diagnosis, and all of the dysplastic as well as the
cancerous lesions were grossly visible to the pathologist (N. H.). Microdissection was not performed.

**MSI.** The MSI status of all of the 148 neoplasms was determined by PCR using fluorometer-labeled primers to amplify markers BAT25, BAT26, D17S250, D3S345, and D2S133 (33). PCR was performed in three separate tubes for markers D17S250, BAT25, and BAT26. Markers D3S345 and D2S133 were multiplexed in the same reaction tube. Primers were fluorescently labeled as follows: BAT26 was labeled with a green dye, tet; BAT25 with a yellow dye, hex; and D3S345, D2S133, and D17S250 were all labeled with a blue dye, fam. PCRs were carried out in 10-μl volumes containing 60 ng of genomic DNA, 1 pmol of each primer, 50 mM KCl, 10 mM Tris, 0.4 mM each dNTP, 1.5 mM MgCl₂, and 0.5 units of Taq DNA polymerase (Promega, Madison, WI). PCRs consisted of an initial denaturation step at 94°C for 4 min, followed by 30 cycles of 94°C for 30 s, 55°C for 30 s, and 72°C for 30 s, and a final extension step at 72°C for 6 min. The annealing temperature varied among primer sets but was between 50 and 60°C. Simultaneous gel electrophoresis of PCR products was performed on 5.25% Long Ranger gels (Bio-Rad, Hercules, CA) containing 6 μl ethanol. Samples were loaded onto 96-lane gels and electrophoresed on an ABI Prism 377 automated DNA sequencer (Perkin-Elmer, Norwalk, CT). Gels were scored in two steps using separate programs. The first program, Genescan (ABI), checked for consistency across all lanes. Consistency was also checked manually. The second program, Genotyper (ABI), assigned allele sizes and derived peak heights in arbitrary fluorescent units. Peak heights were then evaluated by hand, with the color and size of each peak identifying the product being evaluated and the presence of MSI.

Lesions were characterized as MSI-H if they manifested instability at two or more loci, MSI-L if unstable at only one locus, or MSS if showing no instability at any loci. **MSP.** hMLH1 hypermethylation was determined in 13 MSI-H, 16 MSI-L, and 27 MSS lesions. DNA methylation patterns in the hMLH1 promoter were determined by MSP as described previously (34). MSP distinguishes unmethylated from hypermethylated alleles based on sequence alterations produced by bisulfite treatment of DNA, which converts unmethylated, but not methylated, cytosines to uracil, and subsequent PCR using primers specific to either bisulfite treatment of DNA, which converts unmethylated, but not methylated, cytosines to uracil, and subsequent PCR using primers specific to either hMLH1 promoter methylation was determined in 6 (46%) of 13 MSI-H cases, whereas only 1 (6%) of 16 MSI-L cases and 4 (15%) of 27 MSS cases showed this finding. When MSI-H cases were compared with MSI-L and MSS cases together, MSI-H was significantly associated with hMLH1 hypermethylation (P = 0.013, Fisher’s exact test, two-tailed). The difference in hypermethylation rates between MSI-L and MSS cases was not significant (P = 0.635, Fisher’s exact test, two-tailed).

**Immunohistochemistry.** Frozen tissue was thawed on ice, fixed in 10% formalin, and embedded in paraffin blocks. Five-μm sections were mounted on glass slides. Sections were then deparaffinized with xylene for 30 min and rehydrated using graded ethanol. Antigen retrieval was performed using a heat-induced epitope retrieval method (35). Immunoperoxidase staining using diaminobenzidine as chromogen was performed with the TechnMate 1000 automatic staining system (Ventana, BioTek Solutions, Tucson, AZ). Mouse monoclonal antibody to the hMLH1 gene product was used at 1:300 dilution (PharMingen, San Diego, CA). Staining of tumor cells was evaluated as present or absent in stained slides.

**Statistical Correlations.** Analyses were performed using Statview 4.5 and superANOVA software for the Macintosh (SAS Institute Inc., Cary, NC). Two-by-two table contingency analyses were performed using a two-tailed Fisher’s exact test because some numerical values were less than 5.

**RESULTS.** MSI. Of the 148 neoplasms compared with matched normal control tissue, 13 were MSI-H (8.78%), 16 (11%) were MSI-L, and 118 (80%) were MSS. Results of these MSI studies are summarized in Table 1. Interestingly, 13 (81%) of 16 MSI-L lesions showed only mononucleotide instability, whereas 11 (85%) of 13 MSI-H lesions showed dinucleotide instability (3 with dinucleotide instability alone, and 8 with both dinucleotide and mononucleotide instability; P = 0.001 for MSI-L versus MSI-H, Fisher’s exact test, two-tailed).

**MSP.** Results of hMLH1 promoter hypermethylation assays versus MSI studies in IBD neoplasms are summarized in Table 1 and illustrated in Fig. 1. hMLH1 promoter methylation was determined in all of the MSI-H or MSI-L specimens and in 27 of the MSS lesions. Hypermethylation of the hMLH1 promoter occurred in 6 (46%) of 13 MSI-H cases, whereas only 1 (6%) of 16 MSI-L cases and 4 (15%) of 27 MSS cases showed this finding. When MSI-H cases were compared with MSI-L and MSS cases together, MSI-H was significantly associated with hMLH1 hypermethylation (P = 0.013, Fisher’s exact test, two-tailed). The difference in hypermethylation rates between MSI-L and MSS cases was not significant (P = 0.635, Fisher’s exact test, two-tailed). Among the MSI-H lesions, there were two high-grade, one mixed low- and high-grade, and one low-grade dysplasia and two moderately differentiated carcinomas in the hypermethylated subgroup, whereas there were five moderately differentiated carcinomas and one low- and one high-grade dysplasia in the unmethylated subgroup. This difference in frequency of dysplastic lesions was not statistically significant (P = 0.13, Fisher’s exact test, two-tailed). Moreover, 5 of 15 MSI-L unmethylated lesions were dysplasias versus 0 of 1 in the MSI-L hypermethylated subgroup. Similarly, 6 of 23 MSS unmethylated lesions were dysplasias versus

### Table 1. MSI and hMLH1 hypermethylation in IBD-neoplasia

<table>
<thead>
<tr>
<th>Sample numbers</th>
<th>Total</th>
<th>MSI status</th>
<th>hMLH1 methylation status</th>
<th>hMLH1 protein</th>
</tr>
</thead>
<tbody>
<tr>
<td>H4D1, H4D3, H81T, H75D, H85T, H109T</td>
<td>6</td>
<td>MSI-H</td>
<td>Hypermethylated</td>
<td>Absent in 4/4 lesions</td>
</tr>
<tr>
<td>H81T, H11T, H41T, H57T, H96T, H96D, H83T</td>
<td>7</td>
<td>MSI-H</td>
<td>Unmethylated</td>
<td></td>
</tr>
<tr>
<td>H81T</td>
<td>1</td>
<td>MSI-L</td>
<td>Hypermethylated</td>
<td></td>
</tr>
<tr>
<td>H9D5, H9D6, H9D7, H16T, H29T, H30D, H30T3, H32T, H35T, H52T, H53T, H80T, H82T, H84T, H107T</td>
<td>15</td>
<td>MSI-L</td>
<td>Unmethylated</td>
<td>Present in 2/2 lesions</td>
</tr>
<tr>
<td>H30T1, H30T2, H31T2, H31T3</td>
<td>4</td>
<td>MSS</td>
<td>Hypermethylated</td>
<td></td>
</tr>
</tbody>
</table>

* “T” and “D” in sample numbers denote tumors or dysplasias, respectively.

* Tumors were characterized as MSI-H if they manifested instability at two or more loci (or greater than 30% of loci if more than five loci were tested), MSI-L if unstable at only one locus (or less than 30% of loci if more than five loci were tested), and MSS if showing no instability at any loci.

P = 0.013 for methylation status of MSI-H versus MSI-L + MSS (Fisher’s exact test, two-tailed).
of two different MSI-H IBD neoplasms with hypergastric cancers, and endometrial cancers (24–27, 36, 37).

permethylation and gene silencing in MSI-H sporadic non-IBD CRCs, groups, and tumor grades did not correlate with methylation status. No more frequent in the hypermethylated than in the unmethylated 0 of 4 the MSS hypermethylated subgroup. Thus, early lesions were no more frequent in the hypermethylated than in the unmethylated groups, and tumor grades did not correlate with methylation status.

Immunohistochemistry. Six cases, comprising four MSI-H hMLH1 hypermethylated (H75T, H81T, H85T, and H109T) and two MSI-L hMLH1 unmethylated (H80T and H84T) neoplasms, were tested for hMLH1 nuclear protein expression using immunohistochemistry. All four of the hMLH1 hypermethylated tumors showed diminished hMLH1 expression in tumor cell nuclei relative to normal cell nuclei in the same sections. The two unmethylated samples showed abundant expression of hMLH1 nuclear protein. Representative immunohistochemical data are displayed in Fig. 2.

DISCUSSION

The present study suggests that a significant subgroup of IBD neoplasms manifesting MSI-H demonstrate hypermethylation of the hMLH1 gene promoter, and that this hypermethylation is associated with a lack of hMLH1 protein expression. These data are consistent with previous observations showing frequent hMLH1 promoter hypermethylation and gene silencing in MSI-H sporadic non-IBD CRCs, gastric cancers, and endometrial cancers (24–27, 36, 37).

Although 6 of 13 MSI-H IBD neoplasms were hypermethylated, a roughly equivalent proportion (7 of 13) of MSI-H IBD neoplasms were not hypermethylated in the hMLH1 promoter. Notwithstanding the relatively small number of MSI-H cases, this prevalence of unmethylated cases still looms large when one considers that a minority of sporadic CRCs contains known MMR gene mutations (14). MSI in these seven cases could have derived from mutations in any of the known MMR genes; we did not assay for these mutations (14–22, 38). Furthermore, even in sporadic CRCs with MSI, hMLH1 hypermethylation rates are approximately 80%. Thus, MMR gene mutations or other mechanisms must underlie MSI in the remaining 20% of these tumors.

If MSI-L tumors are considered as lying along a continuum leading to full-blown MSI, the rarity of hMLH1 promoter hypermethylation in MSI-L IBD neoplasms can be interpreted to mean that MSI-L CRCs biologically resemble MSS cases; i.e., a single microsatellite mutation may reflect a random event unrelated to any underlying MMR defect, and, thus, may be unrelated to hMLH1 hypermethylation. On the other hand, hMLH1 hypermethylation in 1 of 16 MSI-L and 4 of 27 MSS lesions may reflect “early” hMLH1 gene inactivation, before development of the full-blown MSI-H phenotype: these cases may have developed MMR deficiency too recently to have accumulated large numbers of microsatellite alterations. Data supporting this latter explanation include hMLH1 hypermethylation in MSI-L primary gastric carcinomas (26). A third explanation for the rarity of hypermethylation seen in our MSI-L and MSS lesions is that only one allele was methylated in these tumors. i.e., hypermethylation of one allele could have resulted in hypermethylation by MSP but not in MMR deficiency. The CRC cell line HT-29, which shows only partial methylation of hMLH1 and is MMR-proficient (36), supports this last possibility. And finally, it is also possible that the mechanisms underlying MSI-L differed from those underlying MSI-H: exclusively mononucleotide instability predominated in MSI-L lesions, whereas mixed dinucleotide and mononucleotide instability prevailed in MSI-H lesions, and this difference was statistically significant. That is, the MMR genes correcting dinucleotide instability may differ from those repairing mononucleotide replication errors.

It has long been believed that chronic inflammatory states such as that caused by IBD predispose to cancer development. Mechanisms accounting for this predisposition to malignancy have been proposed


Microsatellite Instability in Inflammatory Bowel Disease-associated Neoplastic Lesions Is Associated with Hypermethylation and Diminished Expression of the DNA Mismatch Repair Gene, hMLH1

A. Steven Fleisher, Manel Esteller, Noam Harpaz, et al.

Cancer Res 2000;60:4864-4868.

Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/60/17/4864

Cited articles
This article cites 53 articles, 25 of which you can access for free at:
http://cancerres.aacrjournals.org/content/60/17/4864.full.html#ref-list-1

Citing articles
This article has been cited by 28 HighWire-hosted articles. Access the articles at:
/content/60/17/4864.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.